Analysis Why the Georgia Senate runoff could reshape North America’s cannabis sector With Democrats still in range of taking the US Senate, the country's biggest operators could pull even further ahead of their Canadian counterparts, says... Jared GnamNovember 18, 2020
Industry update Despite mixed Q1 results, Aurora soars on Biden victory Company stock has surged more than 150% since Nov. 5, even while reporting declining Canadian weed sales Jared GnamNovember 9, 2020
Analysis Analyst lukewarm on Aphria’s US$300M SweetWater acquisition Chris Damas of BCMI is skeptical the craft beer deal will give the Canadian producer a strong foothold in the US Jared GnamNovember 5, 2020
Analysis Bi-partisan cannabis ballot sweep could trigger green wave in neighbour states With NJ to set up its adult market this year, states like NY, CT, PA and MD will follow, says Chris Lindsey of the... Jared GnamNovember 4, 2020
Analysis Pot stock leaders to consider ahead of US election: BCMI Analyst Chris Damas gives investors his industry leaders in Canada and the U.S., which could win big if Democrats take power Jared GnamOctober 28, 2020
Industry update Legalizing weed in Texas would generate billions in tax revenues, report says A mature regulated market could generate US$2.7B in annual sales, and save taxpayers US$311M per year in enforcement costs: Vicente Sederberg LLP Jared GnamOctober 23, 2020
The weed wire Five state cannabis ballots could add US$9B to American market If five states vote green in November, New Frontier Data estimates US$35 billion in legal weed sales by 2025 Jared GnamSeptember 25, 2020
The weed wire Curaleaf reports strong revenue growth despite pandemic setbacks The US operator says it will be the world's biggest weed firm by next quarter, forecasting pro forma revenues as high as US$215 million Jared GnamAugust 18, 2020
The weed wire Canopy’s recreational cannabis sales continue to decline But the major weed company's stock jumped 7% on strong medical and vaporizer sales Jared GnamAugust 10, 2020
CBD FDA issues cannabis research guidelines as CBD industry still hangs in limbo Vermont cannabis lawyer Timothy Fair calls FDA's two-year delay on CBD regulations 'beyond absurd' Jared GnamJuly 24, 2020